As I understand it, the DSMC can look for superior efficacy in the leronlimab arm and deaths in the placebo arm and a recommendation can be made to the FDA to stop the trial and those in the placebo arm be given leronlimab. That's what we're hoping for and trust that these people have enough humanity to act accordingly.